Castle Biosciences is a provider of molecular diagnostics to improve cancer treatment
decisions. DecisionDx®-Melanoma uses tumor biology to provide an individual risk
of melanoma recurrence beyond traditional factor such as AJCC staging criteria and sentinel
lymph node status. DecisionDx®-UM enables accurate staging of five-year metastatic risk in
uveal melanoma and is standard of care in a majority of ocular oncology practices.